PrintFriendly

Print Friendly, PDF & Email

New Medscape Activity Describes Latest Advances in Inhibitor Management

March 26, 2018

“Advances in Managing Inhibitors in Patients with Hemophilia A,” is the newest educational opportunity to become available through Medscape. It is intended for hematologists, pediatricians, nurses and physicians specializing in emergency medicine. The goal of the activity is to discuss recent advances in the understanding of inhibitors in patients with hemophilia A, including the risks associated with inhibitors as well as current and new approaches to management.

Upon completion of this activity, participants will have increased knowledge of:

  • Risks associated with inhibitor development in patients with hemophilia A
  • Current treatment strategies to address inhibitor development in hemophilia A patients
  • Emerging agents in development for treatment of hemophilia A

The activity also includes a link to a new online educational module for patients and families: “What Does It Mean When You Bleed Despite Taking Your Factor?” Developed through a strategic collaboration with the National Hemophilia Foundation and WedMD Education, the activity includes educational content and short videos describing the signs and symptoms of a bleed and a possible inhibitor, tips for adhering to treatment plans and engaging with your hemophilia treatment center. Providers are encouraged to share the module with individuals and families affected by hemophilia, particularly for those who want to be better educated in the event that they encounter a potential inhibitor response to factor therapy.        

Advances in Managing Inhibitors in Patients with Hemophilia A

Steven Pipe, MD; Shannon L. Carpenter, MD; Shannon L. Meeks, MD

CME / ABIM MOC / CE Released: 3/23/2018; Valid for credit through: 3/23/2019

If you are already registered with Medscape follow this link to access this activity. If you are not registered, simply go to Medscape.org where registration is straightforward and free of charge.